GLP-1
-
恒瑞海外NewCo的 GLP-1 公布II期喜报！会是下一个重磅吗？
2024年5月，恒瑞将GLP-1产品组合以1亿美元首付款+1000万美元近期里程碑付款+累计不超过59.25亿美元的里程碑付款+19.9%股权的价格，授权给了当时还名不见经传的Ka…
-
Professor Liping Zhao: Dysbiosis of the core microbiota is the root cause of human obesity！
The video is available for watching, too. Please visit DrugTimes. Many thanks!~
-
【百家争鸣】赵立平教授：核心菌群失调才是人类肥胖的根本原因！
药时代获得赵教授的授权转载，衷心感谢！
-
【Product for Licensing】siRNA Therapeutics Targeting INHBE and another target
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
【Product for Licensing】ALK7-targeting siRNA Therapeutics for fat reduction without muscle loss
If you are interested in this asset or need more information, please contact DrugTimes BD Team at BD@drugtimes.cn or visit our website at https://www.drugtimes.cn
-
Musk’s Hobby Also Sparks a Boom for WuXi AppTec!
For more reports, please follow DrugTimes
-
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
-
【重磅消息】欧盟委员会无条件批准了Novo Holdings对Catalent的165亿美元收购计划
药时代将持续跟踪报道这一重要交易的进展，欢迎广大朋友们关注药时代，获取最新资讯！
-
NASDAQ-listed companies are looking for obesity drugs with the potential for weight loss and muscle gain
If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible!
-
GLP-1触发的 “连招”，何止医美？
GLP-1已成当下MNC研发管线的标配。 除已有大热产品上市的诺和诺德、礼来外，近期包括罗氏、辉瑞也接连宣布其在研GLP-1产品的好消息。 2024年7月15日，国外媒体ENDPO…
